

Certificate of Analysis for MRA-201

Plasmodium falciparum, Strain D10

Catalog No. MRA-201

Product Description: Plasmodium falciparum (P. falciparum), strain D10 was isolated in Papua New Guinea and is generally considered drug sensitive.

Lot¹: 63834913 Manufacturing Date: 30OCT2015

TEST	SPECIFICATIONS	RESULTS Blood-stage parasites present		
Identification by Giemsa Stain Microscopy ²	Blood-stage parasites present			
Antimalarial Susceptibility Profile (in vitro) Half-maximal Inhibitory Concentration (IC50) by SYBR green I® drug sensitivity assay³ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine	Report results Report results Report results Report results Report results	7.1 ± 0.7 nM 5.8 ± 0.7 nM 548.4 ± 88.8 nM 8.0 ± 0.9 nM 37.2 ± 6.0 nM		
Sulfadoxine	Report results	474000 ± 54692 nM		
Genotypic Analysis Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 740 base pairs) MSP2 PCR amplicon analysis ⁴	Consistent with <i>P. falciparum</i> ~ 600-900 base pair amplicon	Consistent with <i>P. falciparum</i> (Figure 1) ~ 900 base pair amplicon		
Level of Parasitemia Pre-freeze ⁵ Post-freeze ⁶	Report results > 1%	4.16% 3.44%		
Viability (post-freeze) ⁷	Growth in infected red blood cells	Growth in infected red blood cells		
Sterility (21-day incubation) Harpo's HTYE broth ⁸ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth	No growth		
Mycoplasma Contamination DNA Detection by PCR	None detected	None detected		

¹MRA-201 was produced by cultivation of MR-MRA-201 lot 60369606 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 μg/mL hypoxanthine and 2.5 μg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 14 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture to maintain 2% hematocrit.

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 5 days.

³A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In Methods in Malaria Research Sixth Edition. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: https://www.mr4.org/Publications/MethodsinMalariaResearch.aspx].

⁴Primer sequences and conditions for PCR are available upon request.

⁵Pre-freeze parasitemia was determined after 14 days post infection by microscopic counts of Giemsa-stained blood smears.

⁶Post-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.



Certificate of Analysis for MRA-201

⁷Viability was confirmed by examination of infected erythrocytes for parasitemia at 5 days post infection.

Figure 1: MRA-201 MSP2 Sequence

TATTATAAAT	TTCTTTATTT	TTGTTACCTT	TAATATTAAA	AATGAAAGTA	AATATAGCAA	CACATTCATA	AACAATGCTT	
ATAATATGAG	TATAAGGAGA	AGTATGGCAA	ATGAAGGTTC	TAATACTAAT	AGTGTAGGTG	CAAATGCTCC	AAATGCTGAT	
ACTATTGCTA	GTGGAAGTCA	AAGGAGTACA	AATAGTGCAA	GTACTAGTAC	TACTAATAAT	GGAGAATCAC	AAACTACTAC	
TCCTACCGCT	GCTGATACTA	TTGCTAGTGG	AAGTCAAAGG	AGTACAAATA	GTGCAAGTAC	TAGTACTACT	AATAATGGAG	
AATCACAAAC	TACTACTCCT	ACCGCTGCTG	ATACCCCTAC	TGCTACAGAA	AGTAATTCAC	CTTCACCACC	CATCACTACT	
ACAGAAAGTT	CAAGTTCTGG	CAATGCACCA	AATAAAACAG	ACGGTAAAGG	AGAAGAGAGT	GAAAAACAAA	ATGAATTAAA	
TGAATCAACT	GAAGAAGGAC	CCAAAGCTCC	ACAAGAACCT	CAAACGGCAG	AAAATGAAAA	TCCTGCTGCA	CCAGAGAATA	
AAGGTACAGG	ACAACATGGA	CATATGCATG	GTTCTAGAAA	TAATCATCCA	CAAAATACTT	CTGATAGTCA	AAAAGAATGT	
ACCGATGGTA	ACAAAGAAAA	CTGTGGAGCA	GCAACATCCC	TCTTAAGTAA	CTCTAGTAAT	ATTGCTTCAA	TAAATAAATT	
ТСТТСТТТТА	ATTTC:							

TGTTGTTTTA ATTTC

Date: 24 MAR 2016

Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC® s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

Support Provided by NIAID

BEI Resources

www.beiresources.org

E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

MRA-201_63834913_24MAR2016

⁸Atlas, Ronald M. <u>Handbook of Microbiological Media</u>. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.